Company Overview of Boston Biomedical, Inc.
Boston Biomedical, Inc. develops cancer therapeutics for patients suffering from cancer. It offers 10 discovery-stage oncology programs and 5 clinical-stage oncology programs including BBI608, a cancer stem cells (CSC) inhibitor in Phase III trials in North America and Australasia; and BBI503, a CSC kinase inhibitor in Phase I trials in North America. The company was founded in 2006 and is based in Cambridge, Massachusetts. As of April 24, 2012, Boston Biomedical, Inc. operates as a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
640 Memorial Drive
Cambridge, MA 02139
Founded in 2006
Key Executives for Boston Biomedical, Inc.
Boston Biomedical, Inc. Key Developments
Similar Private Companies By Industry
|ZymoGenetics Inc.||United States|
|Mergen Ltd.||United States|
|Applied Protein Sciences, LLC||United States|
|Primogenix Inc.||United States|
|Neurolixis, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Boston Biomedical, Inc., please visit www.bostonbiomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.